We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target
Video

The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target

The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target
Video

The First Discovery of a Single Digit Nanomolar Small Molecule Blocker of a Protein-protein Interaction Target



About the Speaker
Dr. Nils Hansen is the CEO and founder of Vipergen ApS. He is the principal inventor of the enabling YoctoReactor® and Binder Trap Enrichment® drug discovery technology platforms. He previously worked for Praecis Pharmaceuticals Inc., (Waltham, MA, USA) and Symphogen A/S, (Copenhagen, Denmark). Dr. Hansen earned his Ph.D. in immunology from the University of Copenhagen, Denmark in 2000 and his M.Sc. in Chemistry and Biotechnology from the University of Aarhus, Denmark in 1996.Abstract
Effective small molecule PPI blocker discovery using high fidelity DNA-encoded libraries and a low-noise homogeneous screening assay. The screen employs a unique principle of trapping small molecule binders together with the protein target in miniscule droplets.
Advertisement